Emerging novel approaches for ALL: inotuzumab ozogamicin

Emerging novel approaches for ALL: inotuzumab ozogamicin

When to Use Inotuzumab Ozogamicin for Adult ALLПодробнее

When to Use Inotuzumab Ozogamicin for Adult ALL

Novel therapeutic approaches in B-progenitor ALLПодробнее

Novel therapeutic approaches in B-progenitor ALL

Phase II trial of inotuzumab ozogamicin to treat MRD+ B-ALLПодробнее

Phase II trial of inotuzumab ozogamicin to treat MRD+ B-ALL

Safety and efficacy of blinatumomab and inotuzumab ozogamicin in multiple relapsed ALLПодробнее

Safety and efficacy of blinatumomab and inotuzumab ozogamicin in multiple relapsed ALL

Inotuzumab ozogamicin & venetoclax in the treatment of B-ALL: findings from a Phase I trialПодробнее

Inotuzumab ozogamicin & venetoclax in the treatment of B-ALL: findings from a Phase I trial

Phase II study of inotuzumab ozogamicin in MRD+ B-ALLПодробнее

Phase II study of inotuzumab ozogamicin in MRD+ B-ALL

What’s next for inotuzumab ozogamicin in ALL?Подробнее

What’s next for inotuzumab ozogamicin in ALL?

Novel ALL treatment strategies: inotuzumab ozogamicinПодробнее

Novel ALL treatment strategies: inotuzumab ozogamicin

Choosing between inotuzumab ozogamicin and blinatumomab in patients with R/R ALLПодробнее

Choosing between inotuzumab ozogamicin and blinatumomab in patients with R/R ALL

Improving the SOC for ALL with inotuzumabПодробнее

Improving the SOC for ALL with inotuzumab

Novel targeted antibodies for R/R B-ALLПодробнее

Novel targeted antibodies for R/R B-ALL

The evolving role of inotuzumab ozogamicin in the treatment of pediatric & older patients with ALLПодробнее

The evolving role of inotuzumab ozogamicin in the treatment of pediatric & older patients with ALL

Exploring novel treatment strategies for Ph-like ALLПодробнее

Exploring novel treatment strategies for Ph-like ALL

Antibody Therapy in ALL: How and Why to Integrate Antibody-Based Treatment Into Patient ManagementПодробнее

Antibody Therapy in ALL: How and Why to Integrate Antibody-Based Treatment Into Patient Management

Outcomes of patients with B-ALL treated with inotuzumab and who have undergone alloSCTПодробнее

Outcomes of patients with B-ALL treated with inotuzumab and who have undergone alloSCT

The value of moving novel agents into the frontline setting in ALLПодробнее

The value of moving novel agents into the frontline setting in ALL

Novel approaches being explored for patients with accelerated and blast-phase MPNsПодробнее

Novel approaches being explored for patients with accelerated and blast-phase MPNs

Emerging Immunotherapies for the Treatment of B Cell MalignanciesПодробнее

Emerging Immunotherapies for the Treatment of B Cell Malignancies